Verrica Pharmaceuticals (VRCA) announced that the first patient was dosed in December 2025 in the global Phase 3 program evaluating YCANTH for the treatment of common warts. The initiation of the global Phase 3 program in common warts is based upon positive results from the Phase 2 COVE-1 clinical trial that evaluated YCANTH for the treatment of common warts.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRCA:
- Verrica Pharmaceuticals Adds Caligan Partner to Board
- Verrica Pharmaceuticals upgraded to Buy from Hold at Brookline
- Verrica Pharmaceuticals files to sell 14.76M shares of common stock for holders
- Verrica Pharmaceuticals: Hold Rating Amid Strategic Debt Retirement and Dilution Concerns
- Verrica Pharmaceuticals Secures $50M Financing Deal